Daniel Brennan
Stock Analyst at TD Cowen
(3.73)
# 738
Out of 4,667 analysts
20
Total ratings
46.67%
Success rate
12.47%
Average return
Main Sectors:
Stocks Rated by Daniel Brennan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QTRX Quanterix | Maintains: Hold | $14 → $16 | $11.02 | +45.19% | 2 | Nov 13, 2024 | |
| LAB Standard BioTools | Maintains: Buy | $2.75 → $2.5 | $1.61 | +55.28% | 3 | Oct 31, 2024 | |
| AVTR Avantor | Maintains: Buy | $30 → $29 | $20.14 | +43.99% | 5 | Oct 8, 2024 | |
| PACB Pacific Biosciences of California | Maintains: Buy | $12 → $2.5 | $1.72 | +45.35% | 2 | Apr 17, 2024 | |
| TMO Thermo Fisher | Maintains: Overweight | $613 → $670 | $512.84 | +30.65% | 1 | Feb 2, 2023 | |
| CRL Charles River Laboratories International | Upgrades: Buy | $177 → $200 | $187.90 | +6.44% | 2 | May 13, 2020 | |
| MTD Mettler-Toledo International | Maintains: Neutral | $755 → $770 | $1,166.90 | -34.01% | 2 | May 8, 2020 | |
| EXAS Exact Sciences | Maintains: Buy | $135 → $115 | $52.70 | +118.22% | 3 | Apr 28, 2020 |
Quanterix
Nov 13, 2024
Maintains: Hold
Price Target: $14 → $16
Current: $11.02
Upside: +45.19%
Standard BioTools
Oct 31, 2024
Maintains: Buy
Price Target: $2.75 → $2.5
Current: $1.61
Upside: +55.28%
Avantor
Oct 8, 2024
Maintains: Buy
Price Target: $30 → $29
Current: $20.14
Upside: +43.99%
Pacific Biosciences of California
Apr 17, 2024
Maintains: Buy
Price Target: $12 → $2.5
Current: $1.72
Upside: +45.35%
Thermo Fisher
Feb 2, 2023
Maintains: Overweight
Price Target: $613 → $670
Current: $512.84
Upside: +30.65%
Charles River Laboratories International
May 13, 2020
Upgrades: Buy
Price Target: $177 → $200
Current: $187.90
Upside: +6.44%
Mettler-Toledo International
May 8, 2020
Maintains: Neutral
Price Target: $755 → $770
Current: $1,166.90
Upside: -34.01%
Exact Sciences
Apr 28, 2020
Maintains: Buy
Price Target: $135 → $115
Current: $52.70
Upside: +118.22%